These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15585972)

  • 41. [Modified release intra-articular drug delivery systems].
    Szabó A; Szabó B; Balogh E; Zelkó R; Antal I
    Acta Pharm Hung; 2012; 82(2):69-74. PubMed ID: 22870779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
    Schmidinger M; Wenzel C; Locker GJ; Muehlbacher F; Steininger R; Gnant M; Crevenna R; Budinsky AC
    Br J Cancer; 2001 Dec; 85(12):1850-2. PubMed ID: 11747325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
    Synold TW; Doroshow JH
    J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-time electrochemical monitoring of drug release from therapeutic nanoparticles.
    Mora L; Chumbimuni-Torres KY; Clawson C; Hernandez L; Zhang L; Wang J
    J Control Release; 2009 Nov; 140(1):69-73. PubMed ID: 19679152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated liposomal doxorubicin in ovarian cancer.
    Green AE; Rose PG
    Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation of complex nano-particles based on alginic acid/poly[(2-dimethylamino) ethyl methacrylate] and a drug vehicle for doxorubicin release controlled by ionic strength.
    Cai H; Ni C; Zhang L
    Eur J Pharm Sci; 2012 Jan; 45(1-2):43-9. PubMed ID: 22079138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of simple chitosan sheet as drug delivery carrier.
    Saito K; Fujieda T; Yoshioka H
    Eur J Pharm Biopharm; 2006 Oct; 64(2):161-6. PubMed ID: 16884897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Organic nanotubes for drug loading and cellular delivery.
    Wakasugi A; Asakawa M; Kogiso M; Shimizu T; Sato M; Maitani Y
    Int J Pharm; 2011 Jul; 413(1-2):271-8. PubMed ID: 21540092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conjugation to biodegradable polymers can detoxify cancer drugs and improve efficacy.
    Future Oncol; 2006 Dec; 2(6):651-3. PubMed ID: 17155892
    [No Abstract]   [Full Text] [Related]  

  • 52. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
    van Lummel M; van Blitterswijk WJ; Vink SR; Veldman RJ; van der Valk MA; Schipper D; Dicheva BM; Eggermont AM; ten Hagen TL; Verheij M; Koning GA
    FASEB J; 2011 Jan; 25(1):280-9. PubMed ID: 20876209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coordination polymer particles as potential drug delivery systems.
    Imaz I; Rubio-Martínez M; García-Fernández L; García F; Ruiz-Molina D; Hernando J; Puntes V; Maspoch D
    Chem Commun (Camb); 2010 Jul; 46(26):4737-9. PubMed ID: 20485835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NeXstar Pharmaceuticals lauches DaunoXome.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular self-assembly of a homopolymer: an alternative to fabricate drug-delivery platforms for cancer therapy.
    Liu J; Huang W; Pang Y; Huang P; Zhu X; Zhou Y; Yan D
    Angew Chem Int Ed Engl; 2011 Sep; 50(39):9162-6. PubMed ID: 21919151
    [No Abstract]   [Full Text] [Related]  

  • 56. A luminescent nanoporous hybrid material based drug delivery system showing excellent theranostics potential for cancer.
    Modak A; Barui AK; Patra CR; Bhaumik A
    Chem Commun (Camb); 2013 Sep; 49(69):7644-6. PubMed ID: 23872783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Liposomal adriamycin: preparation, administration, and toxicity monitoring. Nursing aspects].
    Panzolini S
    Suppl Tumori; 2004; 3(4):S120. PubMed ID: 15206235
    [No Abstract]   [Full Text] [Related]  

  • 58. Inhibition of mouse mammary carcinoma development with doxorubicin in liposomes.
    Vaage J; Working P; Uster P
    Int J Cancer; 1998 Jan; 75(1):158-9. PubMed ID: 9426705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autonomous bacterial nanoswimmers target cancer.
    Zoaby N; Shainsky-Roitman J; Badarneh S; Abumanhal H; Leshansky A; Yaron S; Schroeder A
    J Control Release; 2017 Jul; 257():68-75. PubMed ID: 27744036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heat-Activation Concentrates Chemotherapy in Liver Tumors.
    Abbasi J
    JAMA; 2018 Sep; 320(10):965. PubMed ID: 30208437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.